Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/G13D

G13D

CIViC ID: 81 · Gene: KRAS

Variant Summary

Also known as: GLY13ASP,RS112445441
HGVS: NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A
Variant Type(s): missense_variant
Evidence Items: 14

Evidence Level Distribution

Level B: 6Level C: 3Level D: 5

Evidence Items

Showing CIViC evidence rows where gene = KRAS and variant = G13D.

Level	Type	Direction	Significance	Disease	Drugs	Rating
B	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	4
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	4
D	Predictive	Supports	Resistance	Breast Cancer	Pictilisib	4
B	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	4
B	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	3
C	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab	3
B	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	3
D	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Selumetinib,Dactolisib	2
C	Predictive	Does Not Support	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	2
C	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	2
B	Predictive	Does Not Support	Resistance	Colorectal Cancer	Cetuximab	2
D	Predictive	Supports	Resistance	Colorectal Cancer	Regorafenib Anhydrous	1
D	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	0
B	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	0